Quanterix Corporation announced a series of leadership and governance enhancements designed to support the Company?s next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company?s Board of Directors, effective immediately (November 20, 2025). Dr. Hampton most recently served as President, Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific.
Dr. Sachs is the former Chief Medical Officer and Chief Scientific Officer of Thermo Fisher Scientific. The Company also announced that Bill Donnelly, previously the non-Executive Chair of the Board, has been appointed Executive Chair, and Jeffrey Elliott, a current member of the Board, has been appointed to the newly created role of Lead Independent Director. As Executive Chair, Mr. Donnelly will work closely with the Company?s leadership team and provide support in select strategic and operational areas.
This structure enables Chief Executive Officer Masoud Toloue to continue advancing the Company's key strategic initiatives, including expanding its blood- and tissue-based biomarker menu, launching LucentAD Complete? for Alzheimer's diagnosis, and accelerating growth synergies from the Akoya acquisition. Additionally, Paul Meister and David Walt, Ph.D. are stepping down from the Board after many years of service, effective immediately (November 20, 2025).
With these changes, the Quanterix Board now comprises nine members, seven of whom are independent. Garret Hampton has more than 35 years of experience across life sciences, diagnostics, and oncology. From 2020 to 2024, he served as President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific Inc., where he led a 800-person division focused on oncology diagnostics.
Prior to that, he was Senior Vice President of Clinical Genomics at Illumina Inc., and previously held senior leadership roles at Genentech, Celgene and the Genomics Institute of the Novartis Research Foundation. He currently serves as an independent director of IDEAYA Biosciences Inc. Dr. Hampton earned his Ph.D. in Genetics from University College London and his M.A. and B.S. Natural Science, Genetics, from Trinity College Dublin. Alan Sachs has more than two decades of experience in molecular diagnostics and technology development.
Most recently, he spent nine years at Thermo Fisher Scientific, serving as Chief Medical Officer from 2021 to 2025 and Chief Scientific Officer from 2016 to 2021. In those roles, he led the company?s research and development efforts, championing innovation across disciplines and accelerating the adoption of diagnostic platforms and tests. Prior to that, he served as Vice President and Global Head of Research and Development at Life Technologies Corporation, from 2012 to 2016.
Earlier in his career, he spent a decade at Merck Research Laboratories from 2001 to 2011, where he ran technology development and application, built and led global departments in RNA therapeutics, molecular profiling and translational sciences, and managed complex external collaborations. He began his career as a faculty member at The University of California, Berkeley, where he contributed to the advancement of molecular and cellular biology. Dr. Sachs holds an M.D. and a Ph.D. in Cell Biology from Stanford University and a B.A. in Biological Sciences from Cornell University.
Bill Donnelly has served as a member of the Quanterix Board since August 2023 and has served as Chair since March 2025. Mr. Donnelly has more than 30 years of leadership experience in the life sciences and industrial technology sectors. He spent most of his career at Mettler-Toledo International Inc. Prior to his retirement in 2018 after more than 20 years with the company, he served as Executive Vice President responsible for finance, investor relations, supply chain and information technology.
He joined Mettler-Toledo in 1997 as its Chief Financial Officer. Mr. Donnelly has been a director of Ingersoll Rand Inc. since May 2017 and was appointed Lead Independent Director in November 2021. He has also served as a director of T. Rowe Price Group Inc. since 2023.
Mr. Donnelly holds a bachelor?s degree in business administration from John Carroll University. Jeff Elliott has served as a member of the Quanterix Board since August 2024. Mr. Elliott has more than 20 years of experience in the diagnostics and life sciences industries, with deep expertise in finance, strategy and operations.
Since September 2024, Mr. Elliott has served as a consultant to The Boston Consulting Group Inc. From November 2016 to May 2024, he served as Chief Financial Officer of Exact Sciences Corporation and as Chief Operating Officer from 2021 to 2023. Prior to his appointment as CFO, he served as Vice President of Strategy and Business Development at Exact Sciences. Earlier in his career, Mr. Elliott was a senior equity research analyst at Robert W. Baird & Co., where he covered healthcare companies in the diagnostics and life sciences tools sectors.
Since March 2025, he has been a director of Sera Prognostics Inc. Mr. Elliott earned a B.S. in Business Administration from the University of Illinois at Urbana-Champaign and an M.B.A. from the University of Chicago Booth School of Business. He is also a Chartered Financial Analyst (CFA) charter holder.
